AARA Research Center, Dallas, Texas (Dr Lumry); US HAEA Angioedema Center at University of California San Diego, San Diego, California (Ms Templeton); CSL Behring, King of Prussia, Pennsylvania (Dr Omert); University of California Irvine School of Medicine, Orange, California (Dr Levy).
William Lumry, MD, is in private practice in Dallas, Texas, treating adults and children with allergic diseases and asthma. He actively participates in clinical research projects involving new treatments for asthma, allergic and immune deficiency diseases, and hereditary angioedema in his role as medical director of AARA Research Center. He is also clinical professor of internal medicine at the University of Texas Southwestern Medical School in Dallas and teaches at Parkland Memorial Hospital in Dallas. Dr Lumry is president of the Texas Allergy, Asthma and Immunology Society and a fellow of the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the American College of Physicians. He is also a member of the US Hereditary Angioedema Association Medical Advisory Board on the panels responsible for the Hereditary Angioedema International Working Group, International Consensus, and World Allergy Organization hereditary angioedema consensus documents.
J Infus Nurs. 2020 May/Jun;43(3):134-145. doi: 10.1097/NAN.0000000000000365.
Hereditary angioedema (HAE) is a debilitating condition caused by a functional C1-inhibitor (C1-INH) deficiency and characterized clinically by episodes of subcutaneous or submucosal swelling. C1-INH replacement is highly effective for preventing HAE attacks and can improve health-related quality of life. Once available only for intravenous use, C1-INH is now available as a subcutaneous formulation for self-administration, shown to provide sustained plasma levels of C1-INH and reducing the monthly median HAE attack rate by 95% versus placebo in the phase 3 COMPACT study. Subcutaneously administered C1-INH satisfies multiple unmet needs in the management of patients with HAE.
遗传性血管性水肿（HAE）是一种由功能性 C1 抑制剂（C1-INH）缺乏引起的使人虚弱的疾病，临床上表现为皮下或黏膜下肿胀发作。C1-INH 替代疗法对预防 HAE 发作非常有效，并能改善与健康相关的生活质量。C1-INH 曾经仅可用于静脉使用，现在已有皮下制剂供自我给药，在 3 期 COMPACT 研究中，与安慰剂相比，它显示出能持续提供 C1-INH 的血浆水平，并将每月 HAE 发作的中位数降低 95%。皮下给予 C1-INH 满足了 HAE 患者管理中的多种未满足需求。
